| Natalizumab | Biogen | ||
| 300 mg; Vial |
More Than $1000 mn
|
||
| None |
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. | |||
|
Yes
| |||
| Tysabri | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | **** ****** | **** ****** | **** ****** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ****** - ********* | *** ********* | *** ********* | *** ********* | ********* ********* | ********* ********* | **** ** *** **, **** | ********* ********* | **** ** *** **, **** | **** ** *** **, **** | ********* ********* | ********* ********* | **** ** *** **, **** | ********* ********* | **** ** *** **, **** | **** ** *** **, **** | ********* ********* | ********* ********* | **** ** *** **, **** | ********* ********* | **** ** *** **, **** | **** ** *** **, **** | ********* ********* | **** ** *** **, **** | ********* ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | ********* ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** |
| ************** *********** *** ****** ** *********** ******* | ****** *** ******** ******** ********* *** *****'* ******* | ************** *********** *** ****** ** *********** ******* | *** ** ***** ********** ** ****** **** ********** ************** ** ******* ********* **** ******** | *** ** ***** ********** ** ****** **** ********** ************** ** ******* ********* **** ******** | ******* *** ******** *** ********** ** ****** ******** ** * *********** ******* | ******** ********** *** ******** ******* *** ********* ********** ********** | ******* *** ********* ********* ***** | ******* *** ******** *** ********** ** ****** ******** ** * *********** ******* | ******* ** ********** *** ******** ********** ***** | ****** ** ************* ******* ***** ** ******* *********** ***** **** ************* | ****** ** ********* ***************** ***** *** ** *** ******** ******* | ******** ********** *** ******** ******* *** ********* ********** ********** | ***** *** ** ***** ********** | ******* ** ******** ************ *** ********** ******** **** *********** | ******* ** ********** *** ******** ********** ***** | ******* *** *** ********* ** ** ******* ***** | ******* *** ******** *** ********** ** ****** ******** ** * *********** ******* | ******* ** ********** *** ******** ********** ***** | ****** ** ********* **** ** *** | ******* ** ******** ************ *** ********** ******** **** *********** | ******* ** ********** *** ******** ********** ***** | ***** *** ** ***** ********** | ******* ** ********** *** ******** ********** ***** | ****** ** ********* **** ** *** | ******* *** ******** *** ********** ** ****** ******** ** * *********** ******* | ********* *************** *** ******* ** ************* ** ********* **** ******* ******* | ****** *************** *** ******* ** ************* ** ********* **** ******* ******* | ****** ** ********* **** ** *** | ***** *** ** ***** ********** | ******* ** ******** ************ *** ********** ******** **** *********** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | **** ****** | **** | *** ****** *** **** | ||
| ****** - ********* | ******* | ******** ** ****** | ******** ** *** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|